Ras Pathway Activation and MEKi Resistance Scores Predict the Efficiency of MEKi and SRCi Combination to Induce Apoptosis in Colorectal Cancer

SIMPLE SUMMARY: Inhibition of MEK has been proposed as a means to address mutant RAS colorectal cancer (CRC). However, MEK inhibitor adaptive resistance has led to reduced clinical utility of this new drug. Our studies have suggested the potential for the addition of an SRC inhibitor to prevent the...

Descripción completa

Detalles Bibliográficos
Autores principales: Davis, Thomas Benjamin, Gupta, Shilpa, Yang, Mingli, Pflieger, Lance, Rajan, Malini, Wang, Heiman, Thota, Ramya, Yeatman, Timothy J., Pledger, Warren Jackson
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945886/
https://www.ncbi.nlm.nih.gov/pubmed/35326598
http://dx.doi.org/10.3390/cancers14061451

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945886/
https://www.ncbi.nlm.nih.gov/pubmed/35326598
http://dx.doi.org/10.3390/cancers14061451

Ejemplares similares